Avalyn Pharma
PublicAvalyn Pharma is now publicly traded
The data on this page reflects Avalyn Pharma's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 1, 2026
Last Round
Series D
Jul 22, 2025
Total Funding Raised
$574.3M
Company Overview
Avalyn Pharma is a biopharmaceutical company that develops inhaled therapies for the treatment of rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Avalyn Pharma Comparables
Compare Avalyn Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Calluna Pharma | 56% | |
| InCarda Therapeutics | 56% | |
| FibroNox | 55% |
For institutional investors. Book with your work email.
Avalyn Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 1, 2026 | ||||
| Series D | Jul 22, 2025 | ||||
| Series C | Sep 27, 2023 | ||||
| Series B | Apr 27, 2020 | ||||
| Series A | May 15, 2017 | ||||
Seed | Nov 8, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Avalyn Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series D |
| Perceptive Advisors | Series C, Series D |
| Heartland Healthcare Capital | Series C |
| Eventide Funds | Series D, Series C |
| Xontogeny | Series C |
| F-Prime Capital | Series C, Series B, Series A |
| Edmond de Rothschild | Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_valuationSep 30, 2026
Avalyn Pharma Inc. had an approximately $1.28B market capitalization on Sep 30th '26.
- hiresSep 16, 2026
Avalyn Pharma Inc. appoints pulmonary physician and former senior FDA leader Robert (Bob) J. Meyer, MD, to its Board of Directors in Massachusetts on Sep 16th '26.
- hiresSep 16, 2026
Avalyn Pharma Inc. appoints Bob to its Board of Directors in Massachusetts on Sep 16th '26.
- attends_eventSep 8, 2026
Avalyn Pharma Inc. presents AP01 lung-distribution modeling and patient-survey data at ERS Congress 2026 in Barcelona, Spain, held Sep 5–9, 2026.
- attends_eventAug 24, 2026
Avalyn Pharma Inc. plans to present two posters on patient perspectives in clinical trial participation and AP01 lung distribution modeling at the European Respiratory Society (ERS) International Congress 2026 in Barcelona, Spain, in Sep '26.
For institutional investors. Book with your work email.
Avalyn Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.